PARP2 and cancer: As there are multiple agents on the market that inhibit paralogues, such as trametinib (MEK1, MEK2) and PARP inhibitors (PARP1, PARP2), each of the 27 gene pairs we identified could be considered as targets for therapy development if follow-up studies can identify selectivity for cancer cells.